Biomunex Pharmaceuticals’ Agreement with Onward Therapeutics and Series A Fundraising

Dechert advised Biomunex Pharmaceuticals on the deal.

Biomunex Pharmaceuticals, a French biopharmaceutical company, closed a strategic exclusive worldwide license and co-development agreement with Onward Therapeutics SA for a proprietary bispecific antibody program, as well as its Series A funding round.

Onward Therapeutics, a Swiss development stage oncology company, will also invest in Biomunex, participating in the Series A.

Biomunex Pharmaceuticals is a biopharmaceutical company, based in Paris, France and Cambridge, MA, USA, focused on the discovery and development of breakthrough immunotherapies using its unique and proprietary BiXAb®technology to create next generation bi- and multi-specific antibodies for immuno-oncology.

The Dechert team advising Biomunex included national partner Marie Fillon (Picture) and associate Louis de Chezelles on IP and licensing aspects and partner Anne-Charlotte Rivière and associate Johann Gandilhon on corporate aspects.

Involved fees earner: Louis de Chezelles – Dechert; Marie Fillon – Dechert; Johann Gandilhon – Dechert; Anne-Charlotte Rivière – Dechert;

Law Firms: Dechert;

Clients: Biomunex Pharmaceuticals;

Federica Tiefenthaler

Author: Federica Tiefenthaler